InvestorsHub Logo
Followers 14
Posts 2297
Boards Moderated 0
Alias Born 12/20/2012

Re: MackG post# 271936

Wednesday, 09/04/2019 10:11:42 PM

Wednesday, September 04, 2019 10:11:42 PM

Post# of 403039
Been hearing that for years:


1. http://www.ipharminc.com/press-release/2016/12/19/cellceutix-reports-24-core-phase-2b-clinical-trial-sites-for-oral-prurisol-treatment-of-moderate-to-severe-psoriasis-initiated-and-open-for-screening
in part(regarding prurisol), "...with full study top-line results in 3Q2017."
Actual late 4th q, 2018, after slip sliding quarter by quarter.

2. http://www.ipharminc.com/press-release/2016/10/27/cellceutix-corporation-provides-business-update-and-timeline-of-upcoming-milestones

"Mr. Ehrlich concluded, "To wrap up, the consistent theme across all of our compounds is strong supporting clinical data and a clear path to delivering a meaningful return on investment(if only that were true). We had previously been largely under the radar of Wall Street and institutional investors, but given our success to-date, we are now engaging in a much more aggressive outreach effort. We have a number of important upcoming milestones, that if successful, we believe will drive meaningful value for shareholders."

Too easy to go on, so I'll spare thee.



Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News